# Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)

> **NCT02716766** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 46 (actual)

## Conditions studied

- Carcinoma, Hepatocellular
- Secondary

## Interventions

- **DRUG:** Sorafenib
- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT02716766
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2020-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02716766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02716766, "Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02716766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*